Abstract:
Breast cancer is the most common type of cancer among global women, even though
numerous treatment options for breast cancer have been documented. Lapatinib, a tyrosine
kinase inhibitor, modifies the cellular pathways and halts cell proliferation. The focus of
this study includes the distribution of the drug to the tumor site in high amount and boost
the efficiency of Lapatinib-loaded liposomes as a controlled drug delivery system against
breast cancer. The synthesis of liposomes was followed by drug loading. The cargo was
characterized under XRD, FTIR, SEM, EDX, and zeta analysis techniques. The overall
findings demonstrated that the Liposomal formulation of Lapatinib has a high potential for
sustained release of the drug for cancer therapy. As the successfully synthesized Lapatinibliposomes were stable and exhibited increased in vitro anticancer activity as compared to
free Lapatinib. Our study demonstrates that the combination of Lapatinib with liposomes
improves the drug's long-term viability, effectiveness, and active targeting as a potential
targeted therapeutic molecule for breast cancer treatment. To strengthen the utilization of
this combination therapy in cancer therapy trials, further research is warranted.
